Shares of Trevena Inc. (TRVN) are gathering steam in the run-up to a regulatory catalyst, which is only just days away.
Trevena is a biopharmaceutical company focused on the development of novel medicines for patients with central nervous system conditions. The most advanced drug candidate in the pipeline is Oliceridine, an intravenous analgesic, for the management of moderate to severe acute pain.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com